Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BIBioAge Labs Inc. logo

BioAge Labs Inc. (BIOA)

NASDAQ · Currency in USD
$5.10 ▼ -0.43 (-7.78%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.20 ▲ +0.10 (+1.96%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$5.53
Open
$5.48
Day's Range
$5.06 – $5.48
52 Week Range
$4.81 – $25.96
Volume
464,221
Avg. Volume
875,752
Market Cap
$192.01M
Beta (5Y Monthly)
0.94
PE Ratio (TTM)
--
EPS (TTM)
-$2.11
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$23.50

Profile: BioAge Labs Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
61
CEO
Kristen Fortney

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.68 · Revenue est. $1.48M
DateEst.Actual
Aug 6, 2026-$0.61-$0.58Beat
May 8, 2026-$0.64-$0.52Beat
Mar 24, 2026-$0.83-$0.72Beat
Nov 6, 2025-$0.67-$0.56Beat
Aug 6, 2025-$0.56-$0.60Miss
May 6, 2025-$0.52-$0.36Beat

Analyst view

Consensus price target
$23.50 ▲ +360.8%
Range $8.00 – $40.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on BIOA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.